1. (a) Agrofoglio, L.; Suhas, E.; Farese, A.; Condom, R.; Challand, S.R.; Earl, R.A.; Guedj, R. Tetrahedron1994,50, 10,611–10,670; (b) Borthwick, A.D.; Biggadike, K. Tetrahedron1992,48, 571–623; (c) Huryn, D.M.; Okabe, M. Chem. Rev.1992,92, 1745–1768; (d) Marquez, V.E.; Lim, M.I. Med. Res. Rev.1986,6, 1–40; (e) Hobbs, J.B. InComprehensive Medicinal Chemistry; Hansch, C., Sammers, P.G., Taylor, J.B., Eds.; Pergamon: Oxford, 1990; Vol. 2, 306–322. (f) Hovi, T. InAntiviral Agents: The Development and Assessment of Antiviral Chemotherapy; Field, H.J., Ed.; CRC Press: 1988; Chapter 1, 1–12
2. (a) Katagiri, N.; Takebayashi, M.; Kokufuda, H.; Kaneko, C.; Kanehira, K.; Torihara, M. J. Org. Chem.1997,62, 1580–1581; (b) Berranger, T.; Langlois, Y. Tetrahedron Lett.1995,36, 5523–5526; (c) Hildebrand, S.; Troxler, T.; Scheffold, R. Helv. Chim. Acta1994,77, 1236–1240; (d) Legraverend, M.; Aubertin, A.M.; Obert, G.; Huel, C.; Bisagni, E. Nucleosides Nucleotides1994,13, 915–923; (e) Diaz, M.; Ibarzo, J.; Jimenez, J.M.; Ortuno, R.M. Tetrahedron: Asymmetry1994,5, 129–140; (f) Jung, M.E.; Rhee, H. J. Org. Chem.1994,59, 4719–4720; (g) Nokami, J.; Matsuura, H.; Nakasima, K.; Shibata, S. Chem. Lett.1994, 1071–1074; (h) Asami, M.; Takahashi, J.; Inoue, S. Tetrahedron: Asymmetry1994,5, 1649–1652; (i) Hodgson, D.M.; Witherington, J.; Moloney, B.A. J. Chem. Soc., Perkin Trans. 11994, 3373–3378; (j) MacKeith, R.A.; McCague, R.; Olivo, H.F.; Palmer, C.F.; Roberts, S.M. J. Chem. Soc., Perkin Trans. 11993, 313–314; (k) Jung, M.E.; Rhee, H. Tetrahedron Lett.1993,34, 4449–4452; (l) Evans, C.T.; Roberts, S.M.; Shoberu, K.A.; Sutherland, A.G. J. Chem. Soc., Perkin Trans. 11992, 589–592; (m) Trost, B.M.; Li, L.; Guile, S.D.J. Am. Chem. Soc.1992,114, 8745–8747; (n) Peel, M.R.; Sternbach, D.D.; Johnson, M.R. J. Org. Chem.1991,56, 4990–4993
3. (a) Daluge, S.M.; Martin, M.T.; Sickles, B.R.; Livingston, D.A. Nucleosides Nucleotides Nucleic Acids2000,19, 297–327; (b) Olivo, H.F.; Yu, J. J. Chem. Soc., Perkin Trans. 11998, 391–392; (c) Daluge, S.M.; Good, S.S.; Faletto, M.B.; Miller, W.H.; Clair, M.H.S.; Boone, L.R.; Tisdale, M.; Parry, N.R.; Reardon, J.E.; Dornsife, R.E.; Averett, D.R.; Krenitsky, T.A. Antimicrob. Agents Chemother.1997,41, 1082–1093; (d) Faletto, M.B.; Miller, W.H.; Garvey, E.P.; Clair, M.H.S.; Daluge, S.M.; Good, S.S. Antimicrob. Agents Chemother.1997,41, 1099–1107; (e) Crimmins, M.T.; King, B.W. J. Org. Chem.1996,61, 4192–4193; (f) Kimberlin, D.W.; Coen, D.M.; Biron, K.K.; Cohen, J.I.; Lamb, R.A.; McKlinlay, M.; Emini, E.A.; Whitley, R.J. Antiviral Res.1995,26, 369–401; (g) Daluge, S.M. U.S. Patent 5,034,394,Therapeutic nucleosides, 1991
4. (a) An, G.; Rhee, H. Nucleosides Nucleotides Nucleic Acids2000,19, 1111–1122; (b) Kim, W.; Kim, H.; Rhee, H. Heterocycles2000,53, 219–224; (c) Rhee, H.; Yoon, D.; Jung, M.E. Nucleosides Nucleotides2000,3, 619–628; (d) Crimmins, M.T.; Zuercher, W.J. Org. Lett.2000,2, 1065–1067; (e) Crimmins, M.T.; King, B.W.; Zuercher, W.J.; Choy, A.L. J. Org. Chem.2000,65, 8499–8509; (f) Crimmins, M.T. Tetrahedron1998,54, 9229–9272; (g) Olivo, H.F.; Yu, J. Tetrahedron: Asymmetry1997,8, 3785–3788; (h) Akella, L.B.; Vince, R. Tetrahedron1996,52, 2789–2794; (i) Yoon, D.; Rhee, H. 78thAnnual Meeting of the Korean Chemical Society, Poster Session, oct. 18–19, 1996; (j) Konkel, M.J.; Vince, R. Tetrahedron1996,52, 799–808; (k) Konkel, M.J.; Vince, R. Nucleosides Nucleotides1995,14, 2061–2077
5. (a) Kuang, R.; Ganguly, A.K.; Chan, T.M.; Pramanik, B.N.; Blythin, D.J.; McPhail, A.T.; Saksena, A.K. Tetrahedron Lett.2000,41, 9575–9579; (b) Kapeller, H.; Marschner, C.; Weißenbacher, M.; Griengl, H. Tetrahedron1998,54, 1439–1456. (c) Noble, S.A.; Beddall, N.E.; Beveridge, A.J.; Marr, C.L.P.; Mo, C.L.; Myers, P.L.; Penn, C.R.; Storer, R.; Woods, J.M. Nucleosides Nucleotides1991,10, 487–490